Neurodegeneration is a slow and progressive loss of neuronal cells which ultimately involve cell death. In Parkinson’s disease (PD) and Alzheimer’s disease (AD) accumulation of aggregated proteins and defective mitochondria leads to neuronal cell death. The ubiquitin proteasome system (UPS) and autophagy-lysosomal pathway (ALP) plays a key role in neurodegenerative diseases. Targeted degradation of aggregated proteins and damaged mitochondria are predicted to be neuroprotective and offer transformative therapies for PD and AD.

LifeSensors has developed several tools, innovative technologies, and knowledge solutions for advancing research in the field of neurodegeneration. For example, Parkin E3 ligase is a master regulator of mitochondrial health and is implicated in both PD and AD. Lifesensors has developed unique HTS (High-Throughput System) assays for discovering Parkin modulators. Lifesensors is also developing novel biomarkers for PD and AD.

LifeSensors Offers Assays and Reagents for Neuroscience

  • PROTAC approaches for Tauopathies and α-synucleinopathies
  • Research services on ubiquitin E3 ligases 
  • Biomarker development for Parkinson’s disease / Alzheimer’s disease
  • PD research products 

The pathological processes of neurodegenerative diseases are not fully understood. LifeSensors has developed unique tools like TUBES (Tandem Ubiquitin Binding entities) and state of the art technologies for exploration of these neuronal pathways for therapeutic purposes. LifeSensors developed unique functional tests such as the UbiTest and UbiquantELISA assays (in vitro or cell based) to measure polyubiquitination levels for proteins of interest. The newly developed PROTAC assay technology by LifeSensors enables rapid monitoring of PROTAC mediated ubiquitylation and degradation of Tau protein, which is a hallmark of Alzheimer’s disease.